Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

882 results about "Central nervous system" patented technology

The central nervous system (CNS) is the part of the nervous system consisting of the brain and spinal cord. The CNS is so named because it integrates the received information and coordinates and influences the activity of all parts of the bodies of bilaterally symmetric animals—that is, all multicellular animals except sponges and [[radiata|radially symmetric animals ] such as jellyfish—and it contains the majority of the nervous system. Many consider the retina and the optic nerve (cranial nerve II), as well as the olfactory nerves (cranial nerve I) and olfactory epithelium as parts of the CNS, synapsing directly on brain tissue without intermediate ganglia. As such, the olfactory epithelium is the only central nervous tissue in direct contact with the environment, which opens up for therapeutic treatments. The CNS is contained within the dorsal body cavity, with the brain housed in the cranial cavity and the spinal cord in the spinal canal. In vertebrates, the brain is protected by the skull, while the spinal cord is protected by the vertebrae. The brain and spinal cord are both enclosed in the meninges. Within the CNS, the interneuronal space is filled with a large amount of supporting non-nervous cells called neuroglial cells.

Self-adaptive music intervention system based on multi-modal physiological feedback

The invention discloses a self-adaptive music intervention system based on multi-modal physiological feedback, and belongs to the technical field of monitoring and intervention of emotional states, the self-adaptive music intervention system comprises a multi-modal emotional state evaluation module and a self-adaptive music intervention module, the multi-modal emotional state evaluation module acquires multi-modal physiological information of a user, and the self-adaptive music intervention module performs music intervention on the multi-modal emotional state evaluation module; feature extraction and fusion are carried out on the multi-modal data, and the emotional state is evaluated according to the fused data; and the adaptive music intervention module generates music features matched with the current emotion according to the evaluated emotion state, the music features and preference data of the user, and selects music according to the music features to intervene the user. By the adoption of the method, the wearable forehead lobe three-lead electroencephalogram equipment and the intelligent bracelet are combined, physiological signals of the central nervous system and the autonomic nervous system are collected and analyzed in real time, music intervention is automatically adjusted, a personalized emotion adjusting scheme free of side effects is provided, and a closed-loop mental state regulation and control mechanism is formed.
Owner:BEIJING INST OF TECH

Pyridopyrimidine derivative as KRAS g12c inhibitor for the treatment of brain metastasis

The present disclosure relates generally to methods for treating or preventing central nervous system (CNS) metastases with a KRAS inhibitor, and more specifically to treating CNS metastases with a pyridopyrimidine derivative.
Owner:FRONTIER MEDICINES CORP

Tetrahydrofuramide sodium channel regulator and application thereof in medicine

The invention provides a substituted tetrahydrofuran carboxamide derivative, salt or stereochemical isomer, a pharmaceutical composition containing the substituted tetrahydrofuran carboxamide derivative, application of the substituted tetrahydrofuran carboxamide derivative as a Nav inhibitor and application of the substituted tetrahydrofuran carboxamide derivative in preparation of drugs for treating and / or relieving pain and pain related diseases. The compound provided by the invention has the advantages of high metabolic stability, high oral absorption, better bioavailability, better activity, higher selectivity, better pharmacokinetic property, quicker effect, low side effect on central nervous system and the like.
Owner:ANDIKANG (WUXI) BIOLOGICAL TECH CO LTD

Diagnostic and treatment monitoring based on blood-brain barrier disruption

The disclosure provides technologies that permit detection and / or characterization of brain biomarkers (e.g., disease-associated biomarkers) in non-CNS samples, including by liquid biopsy (e.g., blood, serum, etc.). Among other things, the present disclosure demonstrates that ultrasound opening of the blood brain barrier can achieve detectable increases in brain-derived materials (e.g., brain-derived proteins, neuron-derived extracellular vesicles, and / or cell-free DNA) in readily-sampled systemic liquids.
Owner:INSIGHTEC

Advantageous benzofuran compositions for mental disorders or enhancement

Pharmaceutically active benzofuran compositions for the treatment of mental disorders or for mental enhancement, including for entactogenic therapy. The present invention also includes benzofuran compounds, compositions, and methods for generally modulating central nervous system activity and treating central nervous system disorders.
Owner:TACTOGEN INC

Systems and methods for reducing inflammation in the central nervous system

The present disclosure describes a system for transcutaneous auricular branch vagal nerve stimulation. Stimulation of the vagal nerve is configured to reduce inflammation in the central nervous system. The system includes a first electrode to be attached to a cymba of a patient's ear, a second electrode to be attached to a cavum of the patient's ear, and a flexible substrate to be bent over the ear to secure the system to the patient's ear.
Owner:WASHINGTON UNIV IN SAINT LOUIS

Conjugates of saponin and antisense oligonucleotides for use in the treatment of neurodegenerative diseases

PCT designated stage expiredWO2024261042A1Senses disorderNervous disorderBiological targetNeural Canal
The present invention relates to the fields of therapy and drug delivery. More specifically, disclosed herein are therapeutic methods and pharmaceutical compositions for treating disorders of blood-tissue barrier-shielded organs that harbour substantive populations of post-mitotic neurons, such as the organs derived from neural tube that include the central nervous system and the eye. The disclosed methods and compositions involve localised administration into such organs of an effector component that targets an intracellular biological target, in combination with a saponin component that enhances effective uptake of the effector component into the cells and / or that enhances effective routing of the effector component inside the cells where the biological target is present. For example, the effector component can be an oligonucleotide therapeutic that is targeting a gene product associated with the disorder of the CNS and / or of the eye. Due to cellular uptake-stimulating and / or endosomal escape enhancing effects of the saponin component, the presented herein neuropharmaceutical and ophthalmic compositions for the localised administration into the CNS and / or into the eye, respectively, can be formulated with lower concentrations of the effector component and / or at lower volumes, which confers safety-benefits to the neurons and to the comfort of the patient.
Owner:SAPREME TECH BV

Neurosteroid derivative solid dispersion, preparation method and application thereof, and therapeutic drug for central nervous system disorder related diseases

The invention provides a neurosteroid derivative solid dispersion, a preparation method and application thereof, and a medicine containing a hot-melt extrusion solid dispersion, and belongs to the technical field of pharmacy. The preparation method comprises the following steps: carrying out melt extrusion on a raw material mixture at 125-160 DEG C to obtain the neurosteroid derivative solid dispersion, the mixed material comprises an active component, a plasticizer and a carrier material in a mass ratio of 10: (1-15): (10-90); the active component comprises at least one of a neurosteroid derivative (with a structure as shown in a formula 1), an isomer, a solvate and a pharmaceutically acceptable salt thereof; the plasticizer is selected from one or more of polyethylene glycol, poloxamer and Tween, and the average molecular weight of the polyethylene glycol is 1t; 6000, 6000; active components in the neurosteroid derivative solid dispersion exist in an amorphous state. The neurosteroid derivative in the neurosteroid derivative solid dispersion disclosed by the invention has relatively high oral bioavailability. # imgabs0 #
Owner:HUNAN MINGRUI PHARMACEUTICAL CO LTD

Phenethylamine derivatives, compositions, and methods of use

There are disclosed psychedelic and entactogen compounds, the use of such compounds in the treatment of diseases associated with a serotonin receptor or monoamine transporter, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin receptor or monoamine transporter, such as inflammation, central nervous system (CNS) disorders or psychological disorders with the compounds of the invention.
Owner:CYBIN IRL LTD

Gene therapy for diseases with CNS manifestation

The present disclosure relates generally to viral vectors comprising an engineered transgene capable of crossing the blood brain barrier and their use in treating diseases with central nervous system performance, such as, but not limited to, Hunter Syndrome, Gaucher Disease, and Swefil Syndrome.
Owner:TAKEDA PHARMA CO LTD

Nasal Anti-cancer therapies

Provided herein are methods for treating cancer comprising intranasal administration of an oncolytic virus or an oncolytic virus-based vector, comprised in a mesenchymal stem cell (MSC), an MSC-derived EV, or in an MSC-derived bioxome. Further, the MSCs, MSC-derived EVs, or MSC-derived bioxomes disclosed herein may be used for treating a central nervous system (CNS) related disorder.
Owner:ORGENESIS INC

PH-sensitive humanized anti-transferrin receptor 1 antibody

The invention relates to the technical field of antibodies, in particular to a pH-sensitive humanized anti-transferrin receptor 1 antibody. The invention designs a pH-sensitive human anti-transferrin receptor 1 antibody or an antigen binding fragment thereof, the antibody has good binding activity to TfR1 under a neutral pH condition, the binding activity is obviously reduced or lost under a low pH condition, and the antibody can more efficiently penetrate through a blood-brain barrier to be delivered into the brain through a TfR1-mediated endocytosis transport effect by utilizing the pH-sensitive characteristic, so that the human anti-transferrin receptor 1 antibody or the antigen binding fragment thereof can be applied to the brain. The drug delivery system can be used as a delivery carrier of drugs for treating central nervous system diseases, and has a wide application prospect.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES

Pharmaceutical compositions for treatment of central nervous system disorders

The present invention relates to the fields of therapy and drug delivery. More specifically, disclosed herein are therapeutic methods and pharmaceutical compositions for treating disorders of the central nervous system. The disclosed methods and compositions involve localised administration into such organs of an effector component that targets an intracellular biological target, in combination with a saponin component that enhances effective uptake of the effector component into the cells and / or that enhances effective routing of the effector component inside the cells where the biological target is present. For example, the effector component can be an oligonucleotide therapeutic that is targeting a gene product associated with the disorder of the CNS. Due to cellular uptake-stimulating and / or endosomal escape enhancing effects of the saponin component, the presented herein neuropharmaceutical compositions for the localised administration into the CNS can be formulated with lower concentrations of the effector component and / or at lower volumes, which confers safety-benefits to the neurons and to the comfort of the patient.
Owner:SAPREME TECH BV

Indolizine compounds for the treatment of mental disorders or inflammation

The present invention discloses compounds, compositions, methods for modulating central nervous system activity, methods for treating inflammatory or metabolic disorders, and methods for treating central nervous system disorders, such as depression, anxiety, and trauma- and stressor-related disorders, comprising the indolizines having the structures disclosed herein.
Owner:TACTOGEN INC

Rnai reagent and composition for inhibiting expression of transthyretin (TTR), and use

PCT designated stage expiredWO2025098117A1Organic active ingredientsNervous disorderDiseaseSystemic amyloidosis
An RNAi agent and composition for inhibiting the expression of transthyretin (TTR), which can be used for treating and / or preventing ATTR-related diseases comprising ATTR-PN (transthyretin amyloidosis polyneuropathy), ATTR-CM (transthyretin amyloidosis cardiomyopathy), senile systemic amyloidosis diseases, and leptomeningeal / central nervous system amyloidosis diseases.
Owner:CHENGDU BRILLIANT PHARMA CO LTD

Coenzyme Q10-containing medicine for improving heart activity and preparation method thereof

The invention discloses a coenzyme Q10-containing medicine for improving heart activity and a preparation method thereof, and particularly belongs to the technical field of biological medicines. The medicine comprises functional components and auxiliary materials, wherein the functional components comprise a cactus extract, a calligonum mongolicum extract, an astragalus membranaceus extract, a sea-buckthorn extract and coenzyme Q10; the hypoxia survival time and the load-bearing swimming time of mice can be remarkably prolonged through low, medium and high dose groups of the medicine for improving the heart vitality, the requirement of fatigue caused by high labor intensity for oxygen is further met by enhancing the immunity of the organism, supply of nutrient substances to the brain, the heart, the bones and the muscles of the organism is enhanced, and the effect of improving the heart vitality is achieved. The composition can regulate the activity of central nervous system, promote the normal operation of the body circulation system, relieve and eliminate fatigue and damage to the body caused by fatigue and chronic fatigue, and quickly recover physical strength.
Owner:GUANGDONG RUNHE BIOTECHNOLOGY CO LTD

Double-encapsulated lipid nanoparticles entering brain through nose as well as preparation method and application of double-encapsulated lipid nanoparticles

PendingCN120617545ANervous disorderKetone active ingredientsOlfactory Epithelial CellDrug encapsulation
The invention relates to double-encapsulated lipid nanoparticles entering brain through nose and a preparation method and application thereof, the double-encapsulated lipid nanoparticles comprise lipid nanoparticles, drugs in the lipid nanoparticles and rana odorata lectin coupled to the surfaces of the lipid nanoparticles, and the drugs comprise hydrophilic drugs and hydrophobic drugs. According to the invention, the rana odorata lectin and the lipid nanoparticles are coupled, and the rana odorata lectin can be specifically combined with L-fucose residues expressed by olfactory epithelial cells, so that the adhesion of the lipid nanoparticles to olfactory epithelium during nasal administration is enhanced, and the brain entering efficiency of the lipid nanoparticles is finally improved. After entering the brain, the lipid nanoparticles respond to diseased regions with high active oxygen content so as to release drugs. In addition, double-drug encapsulation can target different pathogenesis of central nervous system diseases, and the limitation that a traditional treatment drug is single in action target is improved.
Owner:CHINA NAT TOBACCO QUALITY SUPERVISION & TEST CENT

Sublingual or buccal dosage forms comprising antioxidants for treatment of central nervous system disorders

Sublingual or buccal dosage forms comprise at least one antioxidant compound, such as N-acetyl cysteine (NAC), or a pharmaceutically acceptable salt thereof. The sublingual or buccal dosage forms are administered for treating central nervous system (CNS) disorders, such as traumatic brain injury or stroke.
Owner:BEYOND BARRIERS THERAPEUTICS INC

Exosome surface modification by using NHS-PEG-NHS and application of exosome surface modification in targeted drug delivery

The invention belongs to the technical field of exosome modification, and particularly relates to an exosome modification method for connecting a target protein to the surface of an exosome by utilizing NHS-PEG-NHS to achieve a targeting or treatment effect, and application of the exosome modification method in targeted central nervous system demyelination disease treatment. In particular to a technology for modifying an exosome to enable the exosome to have targeting property and a preparation method of the exosome. NHS-PEG-NHS is used as a connecting substance, and protein, polypeptide and substances with primary amine groups on the surface can be connected to the surface of an exosome membrane. The modified exosome can load drugs and can be accurately delivered to tissues expressing specific proteins or polypeptides through oral administration, so that the bioavailability and the treatment effect of the drugs are remarkably improved. Taking the NG2 antibody modified cow milk exosome as an example, the NG2 antibody is connected to the surface of the cow milk exosome to target the central demyelination focus area, so that the effective therapeutic dose of the drug in the central focus area is achieved through oral delivery.
Owner:SHAANXI NORMAL UNIV

Pharmaceutical composition containing anisodine or salt thereof and 2-borneol

The invention discloses a pharmaceutical composition which comprises anisodine or salt thereof and 2-borneol or related substances thereof. The pharmaceutical composition provided by the invention has a synergistic effect in treatment of cardia-cerebrovascular diseases, especially central nervous diseases such as acute ischemic stroke, can effectively improve the effect of patients with cerebrovascular diseases, especially central diseases such as acute ischemic stroke, and improves the quality of life.
Owner:NANJING ZHIHE MEDICINE TECH CO LTD

Rehabilitation evaluation system for central nervous system dysfunction patient

A rehabilitation evaluation system for a patient with central nervous system dysfunction comprises the following steps of S1, collecting videos, motion data and pressure data of a user through a data collection layer, S2, uploading the video data to an edge computing server, performing preliminary posture estimation, and S3, performing rehabilitation evaluation. The method comprises the following steps: S1, carrying out edge calculation on the data, S3, transmitting the data subjected to edge calculation to a cloud server for deep modeling analysis of gait and balance parameters, S4, carrying out abnormal mode identification and comparison after parameter analysis, S5, uploading the analyzed data after comparison to a decision application layer, S6, transmitting each parameter and a corresponding processing scheme to a doctor end for a doctor to check, and S5, carrying out data processing. The method has the advantages that through full-link innovation of multi-mode lightweight acquisition, edge cloud hierarchical processing, double-model intelligent diagnosis, reinforcement learning dynamic optimization and visual remote decision, central nervous rehabilitation evaluation extends to a daily life scene from a laboratory, and core breakthrough of precision improvement, efficiency multiplication and personalized enhancement is achieved.
Owner:CENTRAL INTEGRATED MEDICAL MANAGEMENT (NANJING) CO LTD

Edaravone and novel injection for synthesizing (+)-2-borneol and preparation method thereof

The invention discloses a novel injection containing edaravone and high-purity synthesized (+)-2-borneol, because the (+)-2-borneol is prepared by a chemical synthesis process, the curative effect of the (+)-2-borneol is better than that of natural borneol and (+)-2-borneol extracted from the natural borneol under the same dosage, the toxic and side effects can be reduced, and the product quality is more stable; and the established GC-MS analysis method can more accurately control the content of each coexisting substance and better guarantee the shelf life quality. The injection is more suitable for improving the treatment effect on central nervous system diseases, oxidative stress injuries such as diabetes, retinopathy, diabetic peripheral neuropathy and neurodegenerative diseases and thrombus-related diseases.
Owner:NANJING ZHIHE MEDICINE TECH CO LTD

Adeno-associated virus compositions having increased central nervous system, brain, and / or spinal cord enrichment

Described herein are compositions and kits comprising recombinant adeno-associated viruses (rAAVs) with increased transduction enrichment in the central nervous system, brain, and / or spinal cord. The rAAV compositions described herein encapsidate a transgene, such as a therapeutic nucleic acid. The rAAV capsid and capsid proteins described herein comprise a sequence that bind to the TEK receptor tyrosine kinase (TEK) protein and / or tissue factor pathway inhibitor (TFPI) protein to facilitate crossing the blood-brain barrier. Gene therapy using the rAAVs is described. Also described are methods of treating brain-, spinal-, and central nervous system-related diseases and conditions.
Owner:CAPSIDA BIOTHERAPEUTICS INC

(R)-3-(3-chloro-5-fluoro-2-((4-(1h-pyrazol-1-yl)-2-methylquinolin-8-yloxy)methyl)phenyl)morpholine derivatives and related compounds as bradykinin (BK) B2 receptor antagonist for treating skin diseases

The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to said compound(s) for use as in a method of treating a skin disorder; eye disease; ear disease; mouth, throat and respiratory disease; gastrointestinal disease; liver, gallbladder and pancreatic disease; urinary tract and kidney disease; disease of male genitale organs and female genitale organs; disease of the hormone system; metabolic disease; cardiovascular disease; blood disease; lymphatic disease; disorder of the central nervous system; brain disorder; musculoskeletal system disease; allergy disorder; pain; infectious disease; inflammatory disorder; injury; immunology disorder; cancer; hereditary disease; or edema.
Owner:PHARVARIS GMBH

Therapeutic phenethylamine compositions and methods of use

There are disclosed phenethylamine compounds, the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the disclosed compounds.
Owner:CYBIN IRL LTD

Macrophage-polymer lipid nanoparticle composite drug delivery system, preparation method thereof and application of macrophage-polymer lipid nanoparticle composite drug delivery system in cryptococcus infection resistance

The invention discloses a macrophage-polymer lipid nanoparticle composite drug delivery system, a preparation method thereof and application of the macrophage-polymer lipid nanoparticle composite drug delivery system in cryptococcus infection resistance. According to the drug delivery system, alpha-linolenic acid (ALA), high molecular weight chitosan oligosaccharide (HCOS) and amphotericin B (AmB) are used as raw materials to construct nanoparticles AmB-PLHNs, the nanoparticles are loaded in macrophages through the phagocytosis of the macrophages, and the AmB-PLHNs (at) M1 is constructed. AmB is a common medicine for clinically treating Cn infection, but has the problems of toxic and side effects on kidney and incapability of being transferred into the center. The AmB-PLHNs (at) M1 carries AmB-PLHNs to be transferred into the brain according to the blood-brain barrier penetrating characteristic of M1 type macrophages, and the brain entering efficiency of the medicine is improved. By combining the phagocytosis of macrophages on cryptococcus, the inflammation immune regulation function of the macrophages and the bacteriostatic action of the drug-loaded nanoparticles, the drug-loaded nano-particles are used for treating Cn central infection, and the toxic and side effects of AmB are reduced.
Owner:THE NAVAL MEDICAL UNIV OF PLA

Benzofuran salt morphic forms and mixtures for the treatment of mental disorders or mental enhancement

Salt morphic forms, morphic salt mixtures, and specified salt mixtures of pharmaceutically active benzofuran compositions are provided for the treatment of mental disorders or for mental enhancement, including for entactogenic therapy. The present invention also includes salt morphic forms, morphic salt mixtures, and specified salt mixtures of benzofuran compounds, compositions thereof, and methods for generally modulating central nervous system activity and treating central nervous system disorders.
Owner:TACTOGEN INC